Developer docs
API playgroundTry for free, no card

Search company profiles

AdaptVac

Full company profile

uuid0000x6y

Namestring
AdaptVac
Legal namestring
AdaptVac ApS
Websiteurl
adaptvac.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

AdaptVac is a clinical-stage biotechnology company founded in 2017 as a joint venture between NextGen Vaccines ApS (a University of Copenhagen spin-out) and ExpreS2ion Biotechnologies ApS, headquartered in Frederiksberg, Denmark. The company employs 1-10 people and is privately held, with ownership currently split 66% to NextGen Vaccines and 34% to ExpreS2ion following a December 2021 restructuring tied to the AV001 license. The leadership team combines platform co-inventors with biotech operating experience: CEO Dr. Wian de Jongh (15 years biotech, former CSO and co-founder of NASDAQ First North-listed ExpreS2ion), CSO Prof. Adam Sander (main inventor of the cVLP platform), and Chairman Prof. Morten Nielsen (CMC and process design expertise). The company won the EY Entrepreneur Of The Year 2021 award in Life Sciences for Denmark.

The core asset is a proprietary capsid Virus-Like Particle (cVLP) display platform built on the Bacteriophage AP205 capsid protein combined with a proprietary MoonCatcher/Tag iso-peptide pair that enables spontaneous, precise antigen display during E. coli expression. The platform has been validated through Phase 3 clinical testing of the ABNCoV2 COVID-19 vaccine (licensed to Bavarian Nordic), which demonstrated non-inferiority to Comirnaty mRNA vaccine in 622 participants and a well-tolerated safety profile across 4,205 subjects followed for 6 months with no serious adverse events. The pipeline extends to ES2B-C001/AV001 HER2+ breast cancer vaccine (Phase I, licensed to ExpreS2ion, Proof-of-Mechanism reported September 2025), a cVLP Nipah virus vaccine (VICI-Disease consortium, GMP transfer initiated January 2026, Phase 1/2a planned 2027), the panFiloVaxRR broad-spectrum filovirus vaccine for Ebola/Marburg/Sudan (CEPI/EU funded at USD 12.4M over five years), and a placental malaria vaccine (ADVANCE-VAC4PM, €10M EU grant).

AdaptVac's revenue model is licensing-based, monetizing the platform and pipeline candidates through upfront fees, development and sales milestones, and royalties on net sales, supplemented by non-dilutive grant funding from EU Horizon 2020/Horizon Europe, CEPI, the Danish Innovation Foundation, and the Danish Ministry of Health. Notable license economics include the Bavarian Nordic ABNCoV2 deal (€4M upfront, up to €136M in milestones, plus single to double-digit tiered royalties) and the ExpreS2ion AV001 deal (DKK 2.5M upfront, up to DKK 215M in milestones, plus a lower single-digit royalty). Customers are exclusively enterprise pharmaceutical/biotech licensees and institutional funders; the company has no commercial product sales and is pre-revenue on a product basis.

Short descriptiontext

AdaptVac is a clinical-stage Danish biotechnology company developing vaccines via its proprietary capsid Virus-Like Particle (cVLP) display platform, licensed to pharmaceutical partners for COVID-19, HER2+ breast cancer, Nipah virus, filoviruses, and malaria indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHørsholm, Denmark
HQ citystring
Hørsholm
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
virus-like particle vaccines, cVLP display platform, therapeutic cancer vaccines, infectious disease vaccines, vaccine technology licensing
Industry6 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Vaccines
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Royalties
TypeLicensing Royalties
Description

AdaptVac licenses its proprietary cVLP platform technology and pipeline candidates to pharmaceutical partners. Revenue comes from upfront fees, milestone-based payments during development, and royalty payments based on net sales. Examples include: ExpreS2ion license for AV001 (upfront fee DKK 2.5M, aggregated milestone payments up to DKK 215M, plus single-digit percentage royalty); Bavarian Nordic license for ABNCoV2 (upfront payment of 4 MEUR, potential development/sales milestones up to 136 MEUR, plus single to double-digit tiered royalties).

adaptvac.com
2Non-Dilutive Funding
TypeProfessional Services
Description

Company receives grants and consortium funding from government and institutional sources (EU Horizon 2020, Horizon Europe, CEPI, Danish Ministry of Health, Danish Innovation Foundation) for vaccine development programs. Examples include: EUR 2.7M EU grant for PREVENT-nCoV COVID-19 vaccine; EUR 8M EU Horizon Europe grant for Nipah virus vaccine (VICI-Disease); USD 12.4M CEPI/EU funding for filovirus vaccine (panFiloVaxRR); EUR 10M EU grant for placental malaria vaccine (ADVANCE-VAC4PM); DKK 800M from Danish Ministry of Health for Phase III trial.

adaptvac.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1ABNCoV2
Description

COVID-19 vaccine candidate licensed to Bavarian Nordic. Met primary endpoint in Phase 3, demonstrating non-inferiority to Comirnaty mRNA vaccine.

adaptvac.com
+2 more records
Core offering1 text field

AdaptVac develops a proprietary Phase 3 validated capsid Virus-Like Particle (cVLP) display platform using a MoonCatcher/Tag iso-peptide pair on a Bacteriophage AP205 capsid protein, which forms cVLPs during E. coli production. The company applies this platform to develop vaccine candidates against infectious diseases (COVID-19, Nipah, filoviruses, malaria) and therapeutic cancer targets (HER2+ breast cancer), which it licenses to pharmaceutical partners such as Bavarian Nordic and ExpreS2ion for clinical development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Phase 3 non-inferiority to Comirnaty mRNA vaccine demonstrated with ABNCoV2 COVID-19 booster vaccine in 622 participants
+5 more records
Product overview1 text field

AdaptVac is a clinical-stage biotechnology company developing a new class of vaccines using its Phase 3 validated Tag/Catcher cVLP (capsid virus-like particle) display platform. The platform technology utilizes proprietary MoonCatcher/Tag pair with Bacteriophage AP205 capsid protein. The company portfolio includes multiple vaccine candidates: ABNCoV2 (COVID-19 vaccine, Phase 3 completed, licensed to Bavarian Nordic), ES2B-C001 (HER2-targeted breast cancer vaccine, Phase I ongoing, licensed to ExpreS2ion), cVLP Nipah Virus Vaccine (VICI-Disease consortium, entering GMP), panFiloVaxRR (broad-spectrum filovirus vaccine for Ebola/Marburg, CEPI/EU funded), and placental malaria vaccine (ADVANCE-VAC4PM consortium). The platform enables rapid development of vaccines against self-antigens for cancer immunotherapy and infectious diseases.

Product and service6 records
1Tag/Catcher cVLP Display Platform
CategoryVaccine technology platform
Description

Phase 3 validated capsid virus-like particle platform using a proprietary MoonCatcher/Tag iso-peptide pair on a Tag- or Catcher-fused Bacteriophage AP205 capsid protein that spontaneously forms cVLPs during production in E. coli. Validated for safety, scalability, and EU/US regulatory acceptance through Phase 3 clinical testing in ABNCoV2; licensed to pharmaceutical partners and used as the basis for AdaptVac's vaccine pipeline.

2ABNCoV2 (COVID-19 Vaccine)
CategoryProphylactic infectious disease vaccine
Description

COVID-19 vaccine candidate based on AdaptVac's cVLP platform that met its Phase 3 primary endpoint demonstrating non-inferiority to Comirnaty mRNA vaccine, with safety data in 4,205 individuals showing no serious adverse events at 6-month follow-up. Licensed to Bavarian Nordic for clinical development and commercialization.

3ES2B-C001 / AV001 (HER2-targeted Breast Cancer Vaccine)
CategoryTherapeutic cancer vaccine
Description

HER2-targeted therapeutic breast cancer vaccine candidate using the cVLP platform, designed to break self-tolerance against the HER2 self-antigen. Phase I clinical trial ongoing in patients with metastatic HER2-expressing breast cancer at the Medical University of Vienna; licensed to ExpreS2ion Biotechnologies.

4cVLP Nipah Virus Vaccine
CategoryProphylactic infectious disease vaccine
Description

Vaccine candidate against Nipah virus developed through the VICI-Disease consortium with EU Horizon Europe grant funding of €8M. Process transferred to Northway Biotech for GMP manufacture in preparation for a Phase 1/2a clinical study planned to initiate in 2027.

5panFiloVaxRR Filovirus Vaccine
CategoryProphylactic infectious disease vaccine (pandemic preparedness)
Description

Broad-spectrum vaccine candidate targeting orthoebola and orthomarburg viruses including Ebolavirus Zaire, Sudan Ebolavirus, and Marburg virus, with up to 90% case fatality rates. Developed by AdaptVac as consortium lead with CEPI and EU funding of USD 12.4 million over five years to bring a broad-spectrum vaccine into clinical trials and improve outbreak response.

6Placental Malaria Vaccine
CategoryProphylactic infectious disease vaccine
Description

Vaccine candidate aimed at pregnant women to protect against placental malaria, developed by AdaptVac as part of the ADVANCE-VAC4PM consortium with €10 million in EU grant funding for development.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-19
Description

AdaptVac leads a consortium funded by CEPI (Coalition for Epidemic Preparedness Innovations) and the EU with budget of USD 12.4 million over five years to develop a broadly protective vaccine against filoviruses (Ebola and Marburg). The panFiloVaxRR consortium aims to bring a broad-spectrum vaccine into clinical trials and ultimately improve outbreak response.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-28
Description

Process transfer from ExpreS2ion Biotechnologies to Northway Biotech for GMP manufacture of cVLP Nipah virus vaccine in preparation for Phase 1/2a clinical study planned to initiate in 2027.

3VICI-Disease Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

VICI-Disease consortium awarded EU Horizon Europe grant of €8M to develop a Nipah virus vaccine. Consortium consists of AdaptVac, ExpreS2ion, Friedrich-Loeffler-Institut, Radboud university medical center, Leipzig University, University of Copenhagen, PSG Institute of Medical Sciences and Research, and Centre de Recherches Médicales de Lambaréné.

adaptvac.com
4ADVANCE-VAC4PM Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-14
Description

EU awarded €10 million to ADVANCE-VAC4PM consortium to advance development of a safe, effective, and affordable placental malaria vaccine to protect pregnant women and their babies. AdaptVac is a consortium member.

adaptvac.com
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-02-02
Description

Final License Agreement signed with ExpreS2ion whereby ExpreS2ion exclusively licenses in AV001 (HER2-cVLP), a novel breast cancer vaccine candidate. ExpreS2ion pays upfront fee of DKK 2.5 million, aggregated milestone payments of DKK 215 million during development until market approval, and lower single-digit percentage royalty based on net sales. ExpreS2ion owns 34% of AdaptVac.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-07-22
Description

Final license agreement signed with Bavarian Nordic to license the proprietary capsid virus-like particle (cVLP) based SARS-CoV-2 subunit vaccine (ABNCoV2). Bavarian Nordic made an upfront payment of 4 MEUR, with potential future development and sales milestones and single to double-digit percentage-tiered royalties. Total deal value excluding royalties is up to 136 MEUR. ABNCoV2 completed Phase 3 demonstrating non-inferiority to Comirnaty.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-04-24
Description

Manufacturing agreement signed with AGC Biologics for manufacture and scale-up of the COVID-19 (SARS-CoV-2) Coronavirus vaccine. This partnership leverages AGC Biologics global manufacturing expertise to accelerate GMP manufacture.

8PREVENT-nCoV Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-09
Description

EU Horizon 2020 grant of €2.7M awarded to PREVENT-nCoV consortium for COVID-19 vaccine development. Consortium members include AdaptVac, Institute for Tropical Medicine at University of Tübingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, and Laboratory of Virology, Wageningen University.

adaptvac.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Canadian VLP vaccine company acquired by Mitsubishi, using plant-based expression to produce VLP vaccines including a COVID vaccine (Covifenz). Operates a different production modality but competes in the same VLP vaccine category for infectious disease.

TypeEmerging player
Description

Plant-based biologics company with VLP vaccine capabilities (FastPharming system). Smaller, early-stage platform with overlapping interest in infectious disease and oncology vaccines using VLP and recombinant protein approaches.

TypeBroad incumbent
Description

AdaptVac's ABNCoV2 licensee and a leading specialty vaccine company with approved products (JYNNEOS, Rabipur, Encepur). Comparable in infectious disease vaccine development but substantially larger, publicly listed, and with full commercial infrastructure AdaptVac does not possess.

4Valneva
TypeBroad incumbent
Description

European specialty vaccine company (NASDAQ/Euronext listed) developing and commercializing vaccines against infectious diseases with high unmet need (chikungunya, Japanese encephalitis, Lyme). Comparable in infectious disease focus but operates at commercial scale AdaptVac has not yet reached.

TypeDirect peer
Description

Oxford spin-out developing VLP-based vaccines using a proprietary SpyTag/SpyCatcher technology — a closely analogous 'Tag/Catcher' display approach to AdaptVac's MoonCatcher/Tag. Focused on infectious disease vaccines including hepatitis B and malaria.

TypeDirect peer
Description

Clinical-stage biotech developing VLP-based vaccines using MVA-VLP platform technology for infectious disease (COVID, Zika, Ebola, malaria) and immuno-oncology. Comparable platform approach and indication overlap, particularly with AdaptVac's filovirus and malaria programs.

7Emergex Vaccines
TypeEmerging player
Description

UK-based clinical-stage biotech developing T-cell adaptive vaccines using synthetic peptide-coated gold nanoparticles for infectious diseases (dengue, COVID, Zika). Smaller emerging player in the infectious disease vaccine space with overlapping indication set.

TypeDirect peer
Description

Clinical-stage biotech developing enveloped VLP (eVLP) vaccines for infectious disease and oncology, including a hepatitis B vaccine. Most directly comparable US-listed peer by platform technology and stage.

TypeBroad incumbent
Description

NASDAQ-listed vaccine company with a recombinant nanoparticle VLP platform (Matrix-M adjuvant, RSV/COVID/flu products). Direct technology comparable (VLP-based subunit vaccines) but at vastly greater scale, with commercial product approvals and global manufacturing footprint.

TypeDirect peer
Description

AdaptVac's joint-venture partner (34% owner) and licensee of the HER2 cancer vaccine. Operates as a clinical-stage biotech developing vaccines using the same S2 Drosophila cell-line expression platform that complements AdaptVac's cVLP technology — effectively sister companies under shared founder Prof. Wian de Jongh.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AdaptVac

Vaccinesadaptvac.com

AdaptVac is a clinical-stage Danish biotechnology company developing vaccines via its proprietary capsid Virus-Like Particle (cVLP) display platform, licensed to pharmaceutical partners for COVID-19, HER2+ breast cancer, Nipah virus, filoviruses, and malaria indications.

What AdaptVac does

AdaptVac is a clinical-stage biotechnology company founded in 2017 as a joint venture between NextGen Vaccines ApS (a University of Copenhagen spin-out) and ExpreS2ion Biotechnologies ApS, headquartered in Frederiksberg, Denmark. The company employs 1-10 people and is privately held, with ownership currently split 66% to NextGen Vaccines and 34% to ExpreS2ion following a December 2021 restructuring tied to the AV001 license. The leadership team combines platform co-inventors with biotech operating experience: CEO Dr. Wian de Jongh (15 years biotech, former CSO and co-founder of NASDAQ First North-listed ExpreS2ion), CSO Prof. Adam Sander (main inventor of the cVLP platform), and Chairman Prof. Morten Nielsen (CMC and process design expertise). The company won the EY Entrepreneur Of The Year 2021 award in Life Sciences for Denmark.

The core asset is a proprietary capsid Virus-Like Particle (cVLP) display platform built on the Bacteriophage AP205 capsid protein combined with a proprietary MoonCatcher/Tag iso-peptide pair that enables spontaneous, precise antigen display during E. coli expression. The platform has been validated through Phase 3 clinical testing of the ABNCoV2 COVID-19 vaccine (licensed to Bavarian Nordic), which demonstrated non-inferiority to Comirnaty mRNA vaccine in 622 participants and a well-tolerated safety profile across 4,205 subjects followed for 6 months with no serious adverse events. The pipeline extends to ES2B-C001/AV001 HER2+ breast cancer vaccine (Phase I, licensed to ExpreS2ion, Proof-of-Mechanism reported September 2025), a cVLP Nipah virus vaccine (VICI-Disease consortium, GMP transfer initiated January 2026, Phase 1/2a planned 2027), the panFiloVaxRR broad-spectrum filovirus vaccine for Ebola/Marburg/Sudan (CEPI/EU funded at USD 12.4M over five years), and a placental malaria vaccine (ADVANCE-VAC4PM, €10M EU grant).

AdaptVac's revenue model is licensing-based, monetizing the platform and pipeline candidates through upfront fees, development and sales milestones, and royalties on net sales, supplemented by non-dilutive grant funding from EU Horizon 2020/Horizon Europe, CEPI, the Danish Innovation Foundation, and the Danish Ministry of Health. Notable license economics include the Bavarian Nordic ABNCoV2 deal (€4M upfront, up to €136M in milestones, plus single to double-digit tiered royalties) and the ExpreS2ion AV001 deal (DKK 2.5M upfront, up to DKK 215M in milestones, plus a lower single-digit royalty). Customers are exclusively enterprise pharmaceutical/biotech licensees and institutional funders; the company has no commercial product sales and is pre-revenue on a product basis.

AdaptVac firmographics

Firmographics
Name
AdaptVac
Legal name
AdaptVac ApS
Website
https://adaptvac.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
AdaptVac is a clinical-stage Danish biotechnology company developing vaccines via its proprietary capsid Virus-Like Particle (cVLP) display platform, licensed to pharmaceutical partners for COVID-19, HER2+ breast cancer, Nipah virus, filoviruses, and malaria indications.
Ownership category
akta.pro rank

AdaptVac industry classification

Industry
Product category
Vaccines
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines

Keywords

  • Virus-like particle vaccines
  • CVLP display platform
  • Therapeutic cancer vaccines
  • Infectious disease vaccines
  • Vaccine technology licensing

Where AdaptVac is headquartered

Location

Headquarters

HQ city
Hørsholm
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

AdaptVac business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Licensing Royalties: AdaptVac licenses its proprietary cVLP platform technology and pipeline candidates to pharmaceutical partners. Revenue comes from upfront fees, milestone-based payments during development, and royalty payments based on net sales. Examples include: ExpreS2ion license for AV001 (upfront fee DKK 2.5M, aggregated milestone payments up to DKK 215M, plus single-digit percentage royalty); Bavarian Nordic license for ABNCoV2 (upfront payment of 4 MEUR, potential development/sales milestones up to 136 MEUR, plus single to double-digit tiered royalties).
  2. Non-Dilutive Funding: Company receives grants and consortium funding from government and institutional sources (EU Horizon 2020, Horizon Europe, CEPI, Danish Ministry of Health, Danish Innovation Foundation) for vaccine development programs. Examples include: EUR 2.7M EU grant for PREVENT-nCoV COVID-19 vaccine; EUR 8M EU Horizon Europe grant for Nipah virus vaccine (VICI-Disease); USD 12.4M CEPI/EU funding for filovirus vaccine (panFiloVaxRR); EUR 10M EU grant for placental malaria vaccine (ADVANCE-VAC4PM); DKK 800M from Danish Ministry of Health for Phase III trial.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

AdaptVac product offering

Product offering

Core offering

AdaptVac develops a proprietary Phase 3 validated capsid Virus-Like Particle (cVLP) display platform using a MoonCatcher/Tag iso-peptide pair on a Bacteriophage AP205 capsid protein, which forms cVLPs during E. coli production. The company applies this platform to develop vaccine candidates against infectious diseases (COVID-19, Nipah, filoviruses, malaria) and therapeutic cancer targets (HER2+ breast cancer), which it licenses to pharmaceutical partners such as Bavarian Nordic and ExpreS2ion for clinical development and commercialization.

Product overview

AdaptVac is a clinical-stage biotechnology company developing a new class of vaccines using its Phase 3 validated Tag/Catcher cVLP (capsid virus-like particle) display platform. The platform technology utilizes proprietary MoonCatcher/Tag pair with Bacteriophage AP205 capsid protein. The company portfolio includes multiple vaccine candidates: ABNCoV2 (COVID-19 vaccine, Phase 3 completed, licensed to Bavarian Nordic), ES2B-C001 (HER2-targeted breast cancer vaccine, Phase I ongoing, licensed to ExpreS2ion), cVLP Nipah Virus Vaccine (VICI-Disease consortium, entering GMP), panFiloVaxRR (broad-spectrum filovirus vaccine for Ebola/Marburg, CEPI/EU funded), and placental malaria vaccine (ADVANCE-VAC4PM consortium). The platform enables rapid development of vaccines against self-antigens for cancer immunotherapy and infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • ABNCoV2: COVID-19 vaccine candidate licensed to Bavarian Nordic. Met primary endpoint in Phase 3, demonstrating non-inferiority to Comirnaty mRNA vaccine.
  • ES2B-C001
  • cVLP Platform

Products and services

  • Tag/Catcher cVLP Display Platform Phase 3 validated capsid virus-like particle platform using a proprietary MoonCatcher/Tag iso-peptide pair on a Tag- or Catcher-fused Bacteriophage AP205 capsid protein that spontaneously forms cVLPs during production in E. coli. Validated for safety, scalability, and EU/US regulatory acceptance through Phase 3 clinical testing in ABNCoV2; licensed to pharmaceutical partners and used as the basis for AdaptVac's vaccine pipeline.
  • ABNCoV2 (COVID-19 Vaccine) COVID-19 vaccine candidate based on AdaptVac's cVLP platform that met its Phase 3 primary endpoint demonstrating non-inferiority to Comirnaty mRNA vaccine, with safety data in 4,205 individuals showing no serious adverse events at 6-month follow-up. Licensed to Bavarian Nordic for clinical development and commercialization.
  • ES2B-C001 / AV001 (HER2-targeted Breast Cancer Vaccine) HER2-targeted therapeutic breast cancer vaccine candidate using the cVLP platform, designed to break self-tolerance against the HER2 self-antigen. Phase I clinical trial ongoing in patients with metastatic HER2-expressing breast cancer at the Medical University of Vienna; licensed to ExpreS2ion Biotechnologies.
  • cVLP Nipah Virus Vaccine Vaccine candidate against Nipah virus developed through the VICI-Disease consortium with EU Horizon Europe grant funding of €8M. Process transferred to Northway Biotech for GMP manufacture in preparation for a Phase 1/2a clinical study planned to initiate in 2027.
  • panFiloVaxRR Filovirus Vaccine Broad-spectrum vaccine candidate targeting orthoebola and orthomarburg viruses including Ebolavirus Zaire, Sudan Ebolavirus, and Marburg virus, with up to 90% case fatality rates. Developed by AdaptVac as consortium lead with CEPI and EU funding of USD 12.4 million over five years to bring a broad-spectrum vaccine into clinical trials and improve outbreak response.
  • Placental Malaria Vaccine Vaccine candidate aimed at pregnant women to protect against placental malaria, developed by AdaptVac as part of the ADVANCE-VAC4PM consortium with €10 million in EU grant funding for development.

Quantifiable outcome

  • Phase 3 non-inferiority to Comirnaty mRNA vaccine demonstrated with ABNCoV2 COVID-19 booster vaccine in 622 participants
  • +5 more outcomes

Companies that use AdaptVac

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

AdaptVac technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AdaptVac partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and core.

  • CEPI and EU ConsortiumflagshipStrategic or Co-development Partner · 19 June 2025AdaptVac leads a consortium funded by CEPI (Coalition for Epidemic Preparedness Innovations) and the EU with budget of USD 12.4 million over five years to develop a broadly protective vaccine against filoviruses (Ebola and Marburg). The panFiloVaxRR consortium aims to bring a broad-spectrum vaccine into clinical trials and ultimately improve outbreak response.
  • Northway BiotechcoreTechnology or Integration · 28 January 2025Process transfer from ExpreS2ion Biotechnologies to Northway Biotech for GMP manufacture of cVLP Nipah virus vaccine in preparation for Phase 1/2a clinical study planned to initiate in 2027.
  • VICI-Disease ConsortiumcoreStrategic or Co-development Partner · 1 December 2023VICI-Disease consortium awarded EU Horizon Europe grant of €8M to develop a Nipah virus vaccine. Consortium consists of AdaptVac, ExpreS2ion, Friedrich-Loeffler-Institut, Radboud university medical center, Leipzig University, University of Copenhagen, PSG Institute of Medical Sciences and Research, and Centre de Recherches Médicales de Lambaréné.
  • ADVANCE-VAC4PM ConsortiumcoreStrategic or Co-development Partner · 14 June 2022EU awarded €10 million to ADVANCE-VAC4PM consortium to advance development of a safe, effective, and affordable placental malaria vaccine to protect pregnant women and their babies. AdaptVac is a consortium member.
  • ExpreS2ion BiotechnologiesflagshipOEM/ Whitelabel/ Licensing Partner · 2 February 2021Final License Agreement signed with ExpreS2ion whereby ExpreS2ion exclusively licenses in AV001 (HER2-cVLP), a novel breast cancer vaccine candidate. ExpreS2ion pays upfront fee of DKK 2.5 million, aggregated milestone payments of DKK 215 million during development until market approval, and lower single-digit percentage royalty based on net sales. ExpreS2ion owns 34% of AdaptVac.
  • Bavarian NordicflagshipOEM/ Whitelabel/ Licensing Partner · 22 July 2020Final license agreement signed with Bavarian Nordic to license the proprietary capsid virus-like particle (cVLP) based SARS-CoV-2 subunit vaccine (ABNCoV2). Bavarian Nordic made an upfront payment of 4 MEUR, with potential future development and sales milestones and single to double-digit percentage-tiered royalties. Total deal value excluding royalties is up to 136 MEUR. ABNCoV2 completed Phase 3 demonstrating non-inferiority to Comirnaty.
  • AGC BiologicscoreTechnology or Integration · 24 April 2020Manufacturing agreement signed with AGC Biologics for manufacture and scale-up of the COVID-19 (SARS-CoV-2) Coronavirus vaccine. This partnership leverages AGC Biologics global manufacturing expertise to accelerate GMP manufacture.
  • PREVENT-nCoV ConsortiumcoreStrategic or Co-development Partner · 9 March 2020EU Horizon 2020 grant of €2.7M awarded to PREVENT-nCoV consortium for COVID-19 vaccine development. Consortium members include AdaptVac, Institute for Tropical Medicine at University of Tübingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, and Laboratory of Virology, Wageningen University.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

AdaptVac competitors and assessment

Company assessment

Broad incumbents

  • Medicago (Mitsubishi Tanabe Pharma): Canadian VLP vaccine company acquired by Mitsubishi, using plant-based expression to produce VLP vaccines including a COVID vaccine (Covifenz). Operates a different production modality but competes in the same VLP vaccine category for infectious disease.
  • Bavarian Nordic: AdaptVac's ABNCoV2 licensee and a leading specialty vaccine company with approved products (JYNNEOS, Rabipur, Encepur). Comparable in infectious disease vaccine development but substantially larger, publicly listed, and with full commercial infrastructure AdaptVac does not possess.
  • Valneva: European specialty vaccine company (NASDAQ/Euronext listed) developing and commercializing vaccines against infectious diseases with high unmet need (chikungunya, Japanese encephalitis, Lyme). Comparable in infectious disease focus but operates at commercial scale AdaptVac has not yet reached.
  • Novavax: NASDAQ-listed vaccine company with a recombinant nanoparticle VLP platform (Matrix-M adjuvant, RSV/COVID/flu products). Direct technology comparable (VLP-based subunit vaccines) but at vastly greater scale, with commercial product approvals and global manufacturing footprint.

Emerging players

  • iBio: Plant-based biologics company with VLP vaccine capabilities (FastPharming system). Smaller, early-stage platform with overlapping interest in infectious disease and oncology vaccines using VLP and recombinant protein approaches.
  • Emergex Vaccines: UK-based clinical-stage biotech developing T-cell adaptive vaccines using synthetic peptide-coated gold nanoparticles for infectious diseases (dengue, COVID, Zika). Smaller emerging player in the infectious disease vaccine space with overlapping indication set.

Direct peers

  • SpyBiotech: Oxford spin-out developing VLP-based vaccines using a proprietary SpyTag/SpyCatcher technology — a closely analogous 'Tag/Catcher' display approach to AdaptVac's MoonCatcher/Tag. Focused on infectious disease vaccines including hepatitis B and malaria.
  • GeoVax Labs: Clinical-stage biotech developing VLP-based vaccines using MVA-VLP platform technology for infectious disease (COVID, Zika, Ebola, malaria) and immuno-oncology. Comparable platform approach and indication overlap, particularly with AdaptVac's filovirus and malaria programs.
  • VBI Vaccines: Clinical-stage biotech developing enveloped VLP (eVLP) vaccines for infectious disease and oncology, including a hepatitis B vaccine. Most directly comparable US-listed peer by platform technology and stage.
  • ExpreS2ion Biotechnologies: AdaptVac's joint-venture partner (34% owner) and licensee of the HER2 cancer vaccine. Operates as a clinical-stage biotech developing vaccines using the same S2 Drosophila cell-line expression platform that complements AdaptVac's cVLP technology — effectively sister companies under shared founder Prof. Wian de Jongh.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AdaptVac social profiles

Digital presence

AdaptVac financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AdaptVac leadership team

Management profile

Number of profiles

Profiles8 records

AdaptVac funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AdaptVac M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AdaptVac

What does AdaptVac do?

AdaptVac develops a proprietary Phase 3 validated capsid Virus-Like Particle (cVLP) display platform using a MoonCatcher/Tag iso-peptide pair on a Bacteriophage AP205 capsid protein, which forms cVLPs during E. coli production. The company applies this platform to develop vaccine candidates against infectious diseases (COVID-19, Nipah, filoviruses, malaria) and therapeutic cancer targets (HER2+ breast cancer), which it licenses to pharmaceutical partners such as Bavarian Nordic and ExpreS2ion for clinical development and commercialization.

Is AdaptVac a public or private company?

AdaptVac is a private company. It is classified as corporate owned and is currently operating.

When was AdaptVac founded?

AdaptVac was founded in 2017. It employs 1 to 10 people.

Where is AdaptVac based?

AdaptVac is headquartered in Hørsholm, Denmark, in the Europe region.

How does AdaptVac make money?

Two revenue lines are on record. Licensing Royalties are the primary driver. The others are non-Dilutive Funding.

Who are AdaptVac's main competitors?

Broad incumbents on record are Medicago (Mitsubishi Tanabe Pharma), Bavarian Nordic, Valneva and Novavax. Emerging players are iBio and Emergex Vaccines. Direct peers are SpyBiotech, GeoVax Labs, VBI Vaccines and ExpreS2ion Biotechnologies.

Does AdaptVac have an API?

No public API is recorded for AdaptVac.

What industry is AdaptVac in?

AdaptVac's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comExpreS2ion’s associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccineAdaptVac ApS, an associated company of ExpreS2ion Biotechnologies (in which ExpreS2ion holds a 34% stake), will lead a consortium awarded a USD 12.4 million grant from CEPI and the European Union's Horizon Europe Program to develop a novel filovirus vaccine providing all-in-one protection against multiple deadly viruses including Ebolavirus Zaire, Sudan Ebolavirus, and Marburg. The five-year project will advance a vaccine candidate through preclinical studies into planned Phase I/II clinical trials in Gabon and the Netherlands, with AdaptVac contributing its proprietary Virus-like Particle platform technology. If successful and the candidate is outlicensed, ExpreS2ion may receive milestone payments and royalties through its ownership stake in AdaptVac, with the non-dilutive public funding de-risking the early-stage vaccine candidate.CepiPioneering research to develop all-in-one vaccine against some of the world’s most deadly diseasesA global consortium led by AdaptVac, backed by $12.4 million from CEPI and Horizon Europe, is developing a vaccine to protect against Ebola, Marburg, and Sudan Ebola viruses. The project will test vaccine constructs in preclinical studies, with the most promising candidate advancing to Phase 1/2 trials in Gabon and the Netherlands. The work aims to support CEPI's 100 Days Mission for rapid vaccine development.news.cision.comExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine developmentExpreS2ion Biotechnologies has been awarded an 8 million EUR Horizon Europe grant as part of the VICI-Disease consortium to develop a vaccine candidate for the Nipah virus. The project aims to achieve clinical proof-of-concept within four years by leveraging ExpreS2ion's production platform in collaboration with partners including AdaptVac and several research institutions.PR NewswireSignificant progress made in new COVID-19 vaccine developed by the team of Prof SalantiStrong preclinical results for a new COVID-19 vaccine (ABNCoV2) developed by University of Copenhagen, ExpreS2ion Biotech, AdaptVac, and the PREVENT-nCoV consortium were published in Nature Communications on January 12, 2021, showing more than 100-fold higher neutralizing antibody levels compared to existing approved vaccines. A clinical trial application (CTA) for Phase I/II studies has been submitted to Dutch regulators for accelerated review. Attana provided biosensor technology and quality control services throughout the vaccine development process and recently established a strategic partnership with ExpreS2ion.GlobeNewswireBavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 VaccineBavarian Nordic signed a license agreement with AdaptVac to commercialize a COVID-19 vaccine using capsid virus-like particle technology. The deal includes a EUR 4 million upfront payment and potential milestones, with a first clinical study planned for Q4 2020. Bavarian Nordic expects regulatory approvals within 12-18 months, pending external funding.GlobeNewswireBavarian Nordic Enters Agreement with AdaptVac to Advance COVID-19 Vaccine ProgramBavarian Nordic entered an exclusive head of terms agreement with AdaptVac to license its capsid VLP-based SARS-CoV-2 vaccine. The parties aim to finalize the license within two months, with Bavarian Nordic responsible for clinical development and global commercialization. A clinical study is planned later this year.PR NewswireAdaptVac schießt sich mit AGC Biologics zusammen, um COVID-19-Impfstoff zu entwickeln und zu produzierenAGC Biologics announced a partnership with AdaptVac on April 24, 2020, to jointly develop and manufacture a COVID-19 vaccine using AdaptVac's virus-like particle (VLP) technology. AdaptVac is working on the SARS-CoV-2 vaccine as part of the EU-funded PREVENT-nCoV consortium, with the goal of beginning clinical trials by late 2020. Both companies emphasized the urgency of developing a vaccine to combat the pandemic through this collaborative effort.PR NewswireAdaptVac s'associe à AGC Biologics pour développer et produire un vaccin contre le COVID-19AGC Biologics announced a partnership with AdaptVac to develop and produce a COVID-19 vaccine, leveraging AdaptVac's virus-like particle (VLP) technology within the EU-funded PREVENT-nCoV consortium. The collaboration aims to begin clinical trials by the end of 2020, with AdaptVac's CEO highlighting the partnership's importance for rapid vaccine production during the global pandemic. Both companies emphasized their commitment to working together to combat COVID-19, which had infected over 2 million people worldwide by April 2020.PR NewswireAdaptVac se asocia con AGC Biologics para desarrollar y producir una vacuna para el COVID-19AGC Biologics and AdaptVac announced a partnership to develop and produce a vaccine for COVID-19, leveraging AdaptVac's Virus-Like Particle technology. This collaboration aims to accelerate clinical trials by late 2020 as part of the EU Horizon 2020-sponsored PREVENT-nCoV consortium. The agreement ensures rapid production capabilities to address the urgent global demand for a SARS-CoV-2 solution.